Coherus BioSciences To Divest YUSIMRY In $40M Upfront All Cash Transaction
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences (CHRS) has announced the divestment of its biosimilar drug YUSIMRY in a $40 million upfront all-cash transaction.
June 27, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences (CHRS) is divesting its biosimilar drug YUSIMRY in a $40 million upfront all-cash transaction. This move could provide immediate liquidity and potentially refocus the company's strategic priorities.
The divestment of YUSIMRY for $40 million in cash will provide Coherus BioSciences with immediate liquidity, which can be used to fund other strategic initiatives or reduce debt. This is likely to be viewed positively by investors in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100